RJA
IPXL

Raymond James & Associates’s Impax Laboratories, Inc. IPXL Stock Holding History

Raymond James & Associates’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-43,506
Closed -$846K – 3726
2018
Q1 		$846K Buy
43,506
+3,582
+9% +$70.3K ﹤0.01% 2254
2017
Q4 		$665K Buy
+39,924
New +$732K ﹤0.01% 2376
2015
Q2 		– Sell
-16,886
Closed -$791K – 2481
2015
Q1 		$791K Sell
16,886
-15,756
-48% -$627K ﹤0.01% 1799
2014
Q4 		$1.03M Sell
32,642
-3,189
-9% -$93.3K 0.01% 1554
2014
Q3 		$850K Sell
35,831
-1,039
-3% -$26.6K ﹤0.01% 1591
2014
Q2 		$1.11M Buy
36,870
+9,043
+32% +$244K 0.01% 1433
2014
Q1 		$735K Buy
27,827
+5,545
+25% +$139K 0.01% 1593
2013
Q4 		$560K Buy
22,282
+6,716
+43% +$150K ﹤0.01% 1621
2013
Q3 		$319K Buy
15,566
+1,069
+7% +$22.1K ﹤0.01% 1766
2013
Q2 		$289K Buy
+14,497
New +$257K ﹤0.01% 1722

Raymond James & Associates's IPXL Position: Q2 2018 in Review

Raymond James & Associates sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 43,506 shares — an estimated $846K sold.

Raymond James & Associates first reported a position in IPXL in Q2 2013 and held it in 10 quarters. The position peaked at $1.11M in Q2 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

  • Raymond James & Associates reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 43,506 Impax Laboratories, Inc. shares in Q2 2018, an estimated $846K.
  • Raymond James & Associates first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 10 quarters.
  • Raymond James & Associates's Impax Laboratories, Inc. position peaked at $1.11M in Q2 2014.
  • 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.